ENCell Co Ltd
456070
Company Profile
Business description
ENCell Co Ltd is a biopharmaceutical company. The company is engaged in conducting biopharmaceutical contract development and manufacturing (CDMO) service business and cell, gene therapy new drug development business for rare/incurable muscle diseases such as Charcot-Marie-Tooth disease, Duchenne muscular dystrophy, and sarcopenia.
Contact
701 Yeongdong-daero
11th floor
Gangnam-gu
Seoul
KORT: +82 262058050
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
112
Stocks News & Analysis
stocks
Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%
We see faster cloud growth and improved longer-term profitability for Alphabet.
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
With recent structural changes and strong Azure performance, here’s what we think of Microsoft stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,317.20 | 26.50 | -0.28% |
| CAC 40 | 8,225.63 | 0.15 | -0.00% |
| DAX 40 | 24,239.89 | 32.10 | 0.13% |
| Dow JONES (US) | 47,207.12 | 472.51 | 1.01% |
| FTSE 100 | 9,645.62 | 67.05 | 0.70% |
| HKSE | 26,160.15 | 192.17 | 0.74% |
| NASDAQ | 23,204.87 | 263.07 | 1.15% |
| Nikkei 225 | 49,299.65 | 658.04 | 1.35% |
| NZX 50 Index | 13,391.59 | 14.49 | 0.11% |
| S&P 500 | 6,791.69 | 53.25 | 0.79% |
| S&P/ASX 200 | 9,019.00 | 25.20 | -0.28% |
| SSE Composite Index | 3,950.31 | 27.90 | 0.71% |